Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 11;401(10379):858-873.
doi: 10.1016/S0140-6736(22)02125-0. Epub 2023 Jan 19.

Asthma

Celeste Porsbjerg  1 , Erik Melén  2 , Lauri Lehtimäki  3 , Dominick Shaw  4
Affiliations
Review

Asthma

Celeste Porsbjerg et al. Lancet. .

Abstract

Asthma is one of the most common chronic non-communicable diseases worldwide and is characterised by variable airflow obstruction, causing dyspnoea and wheezing. Highly effective therapies are available; asthma morbidity and mortality have vastly improved in the past 15 years, and most patients can attain good asthma control. However, undertreatment is still common, and improving patient and health-care provider understanding of when and how to adjust treatment is crucial. Asthma management consists of a cycle of assessment of asthma control and risk factors and adjustment of medications accordingly. With the introduction of biological therapies, management of severe asthma has entered the precision medicine era-a shift that is driving clinical ambitions towards disease remission. Patients with severe asthma often have co-existing conditions contributing to their symptoms, mandating a multidimensional management approach. In this Seminar, we provide a clinically focused overview of asthma; epidemiology, pathophysiology, diagnosis, and management in children and adults.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CP declares research grants from AstraZeneca, GSK, Novartis, Teva Pharmaceuticals, Sanofi, Chiesi Farmaceutici, and ALK-Abelló; consulting fees from AstraZeneca, GSK, Novartis, Teva Pharmaceuticals, Sanofi, Chiesi Farmaceutici, and ALK-Abelló; honoraria for lectures from AstraZeneca, GSK, Novartis, Teva Pharmaceuticals, Sanofi, Chiesi Farmaceutici, and ALK-Abelló; and fees for being on the advisory board for AstraZeneca, Novartis, Teva Pharmaceuticals, Sanofi, and ALK-Abelló. EM declares consulting fees from ALK-Abelló, AstraZeneca, Chiesi Farmaceutici, Novartis, and Sanofi. EM is a member of the European Respiratory Society Environmental Health Committee. LL declares consulting fees from ALK-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia Group, GSK, Menarini, Novartis, Orion, and Sanofi; honoraria for lectures from ALK-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia Group, GSK, Menarini, Novartis, Orion, and Sanofi; and fees for being on the advisory board for ALK-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia Group, GSK, Menarini, Novartis, Orion, and Sanofi. LL owns shares of Ausculthing OY. DS declares consulting fees from GSK and Novartis; honoraria for lectures from Teva Pharmaceuticals and Chiesi; and travel fees from Chiesi.